Sept 11 — Remembering 11 years later

At around 8 PM, on September 10, 2001 I was on one of the last LaGuardia - Reagan Delta shuttles to leave New York City. I was returning from a trip to the laboratory at the hospital located on the U.S. Military Academy base in West Point, NY.  We had completed a successful AABB blood bank inspection and was returning home to Washington.  It was a trip I had done several times previously as the pathology consultant to Keller Army Community Hospital and would do several more times over the next four years on frequent site visits and to cover frozen sections as Keller did not have a full-time pathologist.  This experience was the nidus for telepathology in the Army.  I figured there had to be an easier way to cover remote frozens than to fly to New York City or drive for hours each way for 15 minutes of work.  

NikkormatFT2 IMGP1333 On this particular trip, leaving LaGuardia, I was able to capture a few images of lower Manhattan and New York harbor. At the time, I was still taking pictures with a film camera (and still do sometimes but it is getting harder to find quality film and processing facilities...). After takeoff I pulled out my old but trusty Nikkormat FT2 camera, snapped on my equally old but reliable 200mm lens and was able to get off 3 exposures. 

The lighting cooperated despite slow film and my telephoto lens.  I like the grainy nature, particularly for black and white photos.  I did not realize what I had on the roll until many months later and saw what are likely some of the last images of the World Trade Center, particularly from the air.  I could not find the original negatives but was able to scan some 4x6 prints I had made.  About 12 hours after I took this picture, the first plane hit the North tower of the World Trade Center. 

WTC1 WTC3

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Hamamatsu – Redefining the art of whole-slide imaging

Hamamatsu-logo-web-PIOB

Virtual Microscopy / NanoZoomer - Products - NanoZoomer-XR 


Nanozoomer-xrHassle-free

  • Perfect scans at a touch of a button. After slides are loaded, running a batch of slides is virtually hands-free.
  • Scanning profiles can be set up for multiple types and/or users.
  • New viewer software, NDP.View2, speeds and simplifies slide viewing.

Error-free

  • Robust mechanics and optics keep the NanoZoomer error-free and stable.
  • NanoZoomer-XR optimizes scanning conditions to ensure users get the best digital images whenever they scan.

Blur-free

  • Dynamic Pre-Focusing technology (patent pending) maintains a sharp focus on the entire specimen during scanning resulting in crisp and clear images.
  • Slides are automatically evaluated for image quality and re-scanned as needed.

The new NanoZoomer-XR

  • Minimizes work load and speeds slide scanning time by automatically and continuously scanning up to 320 slides per batch.
  • Converts, in as little as 30 seconds, a 15 mm x 15 mm area on a glass slide into an outstanding color image.
  • Scans various types of slides including HE-stained and cytology samples.
  • Features a true multi-Z level acquisition for improved accuracy and viewing of thick specimens.
  • An add-on module for fluorescence scanningwill be available soon.

Learn more 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Simagis Digital Pathology Servers Now Support Leica Microsystems Scanners

 Simagislive

HOUSTON--(BUSINESS WIRE)--Smart Imaging Technologies has signed a license agreement with Leica Microsystems and added support for Leica Slide Scanners to Simagis Live Digital Pathology Servers.

“We are committed to our mission of providing interoperability and integration in the fragmented and rapidly evolving space of Digital Pathology. We are happy to assure our clients and partners that they can continue business as usual, regardless of the outcome of technology consolidation between merging vendors”

Simagis Live Digital Pathology servers already support digital slides from most manufacturers of microscopy slide scanners including Aperio, the market leader soon to be acquired by Leica Microsystems. Adding Leica to the list of supported scanners provides pathology community with digital platform that handles slides from both merging companies and delivers unified solution that works with any vendor, now and in the future.

“We are committed to our mission of providing interoperability and integration in the fragmented and rapidly evolving space of Digital Pathology. We are happy to assure our clients and partners that they can continue business as usual, regardless of the outcome of technology consolidation between merging vendors,” said CEO of the Smart Imaging Technologies.

About Smart Imaging Technologies

We provide digital slide servers, image analysis applications and cloud hosting services that make Digital Pathology affordable for practice of any size. With our technology users can easily create, annotate, share and analyze digital slides from any web browser. Our servers support most digital slide formats and can be easily integrated with various scanners for a single click slide upload. Our products can be custom branded and deployed on premises or the cloud to deliver unified digital pathology solutions across geographic boundaries. For details about technology and solutions manufacturers and integrators may contact support@simagis.us. End users can learn more and sign-up for free web service at web-pathology.net.

Contacts

Smart Imaging Technologies

Evgenia Harris, 713-589-3500

 

 

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Free Webinar: Analyzing IHC Images Using Image-Pro Premier for Research Pathology

Free Webinar: Analyzing IHC Images Using Image-Pro Premier for Research Pathology

September 11, 2012 1pm-2pm EDT Register

Media Cybernetics invites you to attend the free webinar, “Analyzing IHC Images Using Image-Pro Premier for Research Pathology”, Tuesday, September 11, 2012  at 1pm-2pm EDT. 

The Webinar will introduce the features available within Image-Pro Premier image analysis software to set up and create your own image analysis protocols for the analysis of IHC stained samples.  Examples using IHC stained tissue and nuclei will be demonstrated during the webinar.       

Attendees will learn how to: 

  • Evaluate image quality
  • Apply background correction to correct for uneven illumination when required
  • Use image processing techniques to enhance segmentation as related to IHC samples
  • Set up Count/Size for analyzing single or multiple stains
  • Introduce Smart Segmentation, which enables the segmentation of difficult-to-analyze features
  • Configure Data Collector to accumulate data from multiple images


Register

About the Presenter: 
Jeff Knipe is an Image Analysis Trainer with Media Cybernetics. Jeff has extensive hands-on experience in scientific image processing and analysis of both biological and industrial imaging applications.

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Meaningful Use Stage 2: Are You Ready?

Final stage 2 MU rule offers healthcare providers some compromises and EHR tweaks, and also requires greater patient engagement.

By Nicole Lewis,  InformationWeek 
September 04, 2012
URL: http://www.informationweek.com/healthcare/policy/meaningful-use-stage-2-are-you-ready/240006670 


InformationWeek-HealthcareUnder the Meaningful Use stage 2 final rule, eligible professionals (EPs) working in a hospital can apply for incentive payments if they can demonstrate that they've acquired a certified electronic health record (EHR), and are using it in lieu of the hospital's EHR. To qualify, EPs must show that they implemented the EHR and maintain the system, including supporting hardware and interfaces needed to achieve meaningful use, without receiving reimbursements from the hospital.

"We know that there are EPs who work within certain areas or unit of hospitals--for example, neonatal care--but use entirely separate systems, and this application process will allow those EPs to ask for a redetermination of their hospital-based status based on those factors," a spokesman for the Centers for Medicare & Medicaid Services (CMS) told InformationWeek HealthcareAdTech Ad

Expanding the criteria for EPs to apply for incentive payments is one of the many changes incorporated into the Meaningful Use stage 2 final rule, a 672-page document recently published by CMS.


Ipad_HC_lg2Many of the changes address real-world concerns that healthcare providers face as they prepare their systems to meet Meaningful Use criteria, said Dr. Farzad Mostashari, National Coordinator for Health IT at the Office of the National Coordinator for Health Information Technology.

[ For more on Meaningful Use stage 2, see Meaningful Use Stage 2 Rules Finalized. ]

"What you will see [in the stage 2 final rule] is some compromises frankly between the aspirational goals and the realities of where the market is and the pressures on providers and vendors in terms of timeline," Mostashari said during a webcast August 24 hosted by the National eHealth Collaborative.


Meaningful useExtending the timeline to meet Meaningful Use stage 1 deadlines is one area of compromise. In the stage 1 Meaningful Use regulations, CMS established a timeline that required providers to progress to stage 2 criteria after completing two years in the incentive program. This original timeline would have required Medicare providers who first demonstrated Meaningful Use in 2011 to meet the stage 2 criteria in 2013.

However, CMS pushed back the timeline by one year. The earliest that the stage 2 criteria will be effective is fiscal year 2014 for eligible hospitals and critical access hospitals (CAH), or calendar year 2014 for EPs.

Hospitals and physicians must also keep in mind that many of the stage 1 requirements that have been carried forward to stage 2 have a concomitant rise in threshold levels, according to Rob Anthony, a health specialist in the Office of eHealth Standards and Services at CMS.

Explaining the new requirements during the webcast, Anthony said health providers must show that more than 50% of prescriptions are completed through electronic prescribing, up from the stage 1 threshold of 40%. Reporting of demographic information, vital signs, and smoking status has moved from 50% in stage 1 to more than 80% in stage 2. CMS also raised the requirement for reporting instances of clinical decision support and intervention from one to five. These interventions include reporting on drug-to-drug interactions and drug allergy interaction alerts.

Turning to clinical quality measure (CQM) reporting in stage 2, beginning in 2014 EPs must report on nine out of 64 total CQMs, and eligible hospitals and CAHs must report on 16 out of 29 total CQMs.

In addition, all providers must select CQMs from at least three of the six key healthcare policy domains recommended by the Department of Health and Human Services' National Quality Strategy. These are: 1. Patient and Family Engagement; 2. Patient Safety; 3. Care Coordination; 4. Population and Public Health; 5. Efficient Use of Healthcare Resources; and 6. Clinical Processes/Effectiveness.

Stage 2 will also focus more intensely on facilitating patients' access to their records, and replaces stage 1 objectives that call for clinicians to provide electronic copies of health information or discharge instructions, with the stage 2 objectives that allow patients to access their health information online.

For EPs, stage 2 requires that patients have the ability to view online, download, and transmit their health information within four business days of the information being available to the EP. Eligible hospitals and CAHs are required to provide patients the ability to view online, download, and transmit their health information within 36 hours after discharge from the hospital.

Patients must also do their part in stage 2, which calls for more than 5% of patients to send secure messages to their EP, and more than 5% of patients to access their health information online. CMS is introducing exclusions based on broadband availability in the provider's county.

Stage 2 also facilitates batch reporting. Starting in 2014, groups can submit attestation information for all of their individual EPs in one file for upload to the attestation system, rather than having each EP individually enter data.

In the stage 2 criteria, the feds emphasized the need to exchange health information between providers to improve care coordination for patients. One of the core objectives requires EPs, eligible hospitals, and CAHs who transition or refer a patient to another care setting or provider to furnish a summary of care record for more than 50% of those transitions of care and referrals.

Additionally, there are new requirements for the electronic exchange of summary of care documents: EPs, eligible hospitals, and CAHs that transition or refer their patient to another care setting or provider must electronically provide a summary of care record for more than 10% of transitions and referrals.

The EP, eligible hospital, or CAH that transitions or refers a patient to another care setting or provider must either: a) conduct one or more successful electronic exchanges of a summary of care record with a recipient using technology that was designed by a different EHR developer than the sender's, or b) conduct one or more successful tests with the CMS-designated test EHR during the EHR reporting period.

InformationWeek Healthcare brought together eight top IT execs to discuss BYOD, Meaningful Use, accountable care, and other contentious issues. Also in the new, all-digital CIO Roundtable issue: Why use IT systems to help cut medical costs if physicians ignore the cost of the care they provide? (Free with registration.)


 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Educational Flow Cytometry Video (Humor)

One things for sure, you will not hear the words: multineage dysplasia, macrophages, bcl-6, S-phase, monoclonal, Burkitt’s, Rituxin, MDS, AML, translocated genes, APL, Auer rods, all-trans retinoic acid, DIC, CD45 or CD117 all in the same music video again ever.

From DrdoubleB who also produced among other educational pathology videos, Dynamite Case about an interesting surgical pathology case at the University of Florida.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Leopold Koss, MD Passes Away


Obituary_505366cb43bbeLeo Koss 00Leopold G. Koss MD, passed away at his home in New York City, September 11, 2012. Born in Gdansk, Poland in 1920, Leo (as he was known to all who loved him) miraculously survived the Holocaust and became a refugee in Switzerland where he finished the medical studies he had started in Vienna before the War and continued in Brussels and Montpellier. When he arrived in New York in 1947 with his wife and baby son and $20 in his pocket, he spoke no English. Yet, with his prodigious intellect and devotion to science, he rose to the top of his field in his adopted country. He was a pioneer in the field of Cytopathology and was the author of the seminal book on the subject, "Diagnostic Cytology and It's Histopathologic Bases," which appeared in five editions and was recently translated into Chinese. Over his long career, he also wrote numerous other medical books and hundreds of scientific papers. Dr. Koss was chairman emeritus of the Department of Pathology at Montefiore Hospital and the Albert Einstein College of Medicine, which was renamed in his honor. He will be remembered by all who knew him as a man of great intelligence, culture and wit. He was a gifted storyteller who could, depending on his audience, recite French love poetry, sing baudy ditties or quote Caesar's Gallic Wars in the original Latin He is survived by his three sons, Michael, Andrew, and Richard as well as 4 grandchildren. A memorial service will be held at Riverside Memorial Chapel on October 26 at 2 pm. In lieu of flowers, donations can be made in his honor to the Visiting Nurse Service of NYC whose dedicated employees cared for him at the end of his life with unquestioned respect and love.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Free Webinar: What are the Technical Barriers to the Adoption of Digital Pathology

September 19, 2012 | 11:00AM - 12:00PM EST


Webinar Banner 2

This webinar is the second in the DPA, Association of Pathology Informatics (API), and CAP Today's series of one-hour webinars focusing on the barriers to adoption of digital pathology. Technical Barriers to the Adoption of Digital Pathology will feature Sean Costello, Head of Product Management - Digital Pathology at Leica Microsystems, and Kim Dickinson, Senior Medical Director - Integrated Oncology at US Labs. The webinar will be moderated by Robert McGonnagle, publisher of CAP Today.

All of the webinars in this series serve as a bridge between the recent, comprehensive article about regulatory aspects of digital pathology that appeared in CAP Today (see: Regulators Scanning the Digital Scanners) and the two most important, national conferences focusing on digital pathology, Pathology Visions 2012, the annual conference of the DPA, to be held October 28-31, 2012 and Pathology Informatics 2012 to be held October 9 – 12, 2012 in Chicago.

There is no charge to participate in the webinar, however advance registration is required.


Webinar_Register

ARE YOU A MEMBER OF API, CAP, OR ANOTHER ASSOCIATION?

Members of AACR, ACVP, API, APF, ASCO, ASCAP, CAP, CSP, NSH, STP, and USCAP receive registration discount for Pathology Visions 2012.

DPA members aren’t the only association members that will have the opportunity to receive a discounted registration for Pathology Visions 2012. A special affiliate rate has been negotiated for members of the following organizations: AACR, ACVP, API, APF, ASCO, ASCAP, CAP, CSP, NSH, STP, and USCAP. The Affiliated Association & Society registration is all-inclusive.

If you are a member of any of these associations look for an e-mail from your association with registration instructions and a discount code or contact the DPA staff for more information.

Register Now Button

 

Webinar Banner 2 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Surgery Has a More Profound Effect Than Anesthesia on Brain Pathology and Cognition in Alzheimer’s Animal Model

Newswise PHILADELPHIA A syndrome called post-operative cognitive decline has been coined to refer to the commonly reported loss of cognitive abilities, usually in older adults, in the days to weeks after surgery. In fact, some patients time the onset of their Alzheimers disease symptoms from a surgical procedure. Exactly how the trio of anesthesia, surgery, and dementia interact is clinically inconclusive, yet of great concern to patients, their families and physicians.

A year ago, researchers at the Perelman School of Medicine at the University of Pennsylvania reported that Alzheimer's pathology, as reflected by cerebral spinal fluid biomarkers, might be increased in patients after surgery and anesthesia. However, it is not clear whether the anesthetic drugs or the surgical procedure itself was responsible. To separate these possibilities, the group turned to a mouse model of Alzheimers disease.

The results, published online this month in the Annals of Surgery, shows that surgery itself, rather than anesthesia, has the more profound impact on a dementia-vulnerable brain.

The team, led by Roderic Eckenhoff, MD, Austin Lamont Professor of Anesthesia, exposed mice with human Alzheimer disease genes, to either anesthesia alone, or anesthesia and an abdominal surgery. The surgery was similar to appendectomy or colectomy, very common procedures in humans. They found that surgery causes a lasting increase in Alzheimers pathology, primarily through a transient activation of brain inflammation. Also, a significant cognitive impairment persisted for at least 14 weeks after surgery compared to controls receiving anesthesia alone. Neither surgery nor anesthesia produced changes in normal non-transgenic animals.

In the mice, there was a clear and persistent decrement in learning and memory caused by surgery as compared with inhalational anesthesia but only in the context of a brain made vulnerable by human Alzheimer-associated transgenes, notes Eckenhoff.

He also notes that at the time of surgery, the AD mice showed no outward symptoms of AD, despite having subtle evidence of ongoing neuropathology. This timeline is analogous to both the age range and cognitive status of many of our patients presenting for a surgical procedure and suggests the window of vulnerability to surgery of the Alzheimers brain extends into this pre-symptomatic period, says Eckenhoff. This period might be analogous to what is now called prodromal AD.

On the other hand, cautions Maryellen Eckenhoff, PhD, a neuroscientist on the team, the brain vulnerability seen in the AD mice may not translate well to people. The AD mice used, like all current mouse models of Alzheimer disease, more closely resemble the situation in familial Alzheimer disease, which constitutes only a small minority of patients. She points out that it is not yet clear whether results from AD mouse models will represent patients who eventually get late-onset, or sporadic Alzheimer disease. These mice are, however, the current standard of choice for screening new drugs and have yielded considerable insight into Alzheimer pathogenesis.

The mechanism linking surgery and the cognitive effects seems to be inflammation. An inflammatory process is well known to occur as a result of surgery, at least outside the central nervous system. How this inflammatory process gains access to the brain, and accelerates AD pathology in a persistent way is still unclear.

Postoperative cognitive decline has not been convincingly demonstrated to persist after three months in most people, and whether it predicts later dementia is still unclear. This study suggests that in the setting of a vulnerable brain, the cognitive deficits after surgery might be irreversible.

However, the finding that inflammation is the underlying mechanism, immediately suggests a strategy for mitigating injury. Human studies will be needed to first confirm these findings and then begin to deploy anti-inflammatory strategies to minimize injury, adds Eckenhoff. As a profession, doctors need to understand the long-term implications of our care, both positive and negative, and do all we can to delay the onset of dementia.

Here is the original post:
Surgery Has a More Profound Effect Than Anesthesia on Brain Pathology and Cognition in Alzheimer's Animal Model

Surgery more profound effect than anesthesia on brain pathology, cognition in Alzheimer’s mice

Public release date: 14-Sep-2012 [ | E-mail | Share ]

Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine

PHILADELPHIA A syndrome called "post-operative cognitive decline" has been coined to refer to the commonly reported loss of cognitive abilities, usually in older adults, in the days to weeks after surgery. In fact, some patients time the onset of their Alzheimer's disease symptoms from a surgical procedure. Exactly how the trio of anesthesia, surgery, and dementia interact is clinically inconclusive, yet of great concern to patients, their families and physicians.

A year ago, researchers at the Perelman School of Medicine at the University of Pennsylvania reported that Alzheimer's pathology, as reflected by cerebral spinal fluid biomarkers, might be increased in patients after surgery and anesthesia. However, it is not clear whether the anesthetic drugs or the surgical procedure itself was responsible. To separate these possibilities, the group turned to a mouse model of Alzheimer's disease.

The results, published online this month in the Annals of Surgery, shows that surgery itself, rather than anesthesia, has the more profound impact on a dementia-vulnerable brain.

The team, led by Roderic Eckenhoff, MD, Austin Lamont Professor of Anesthesia, exposed mice with human Alzheimer disease genes, to either anesthesia alone, or anesthesia and an abdominal surgery. The surgery was similar to appendectomy or colectomy, very common procedures in humans. They found that surgery causes a lasting increase in Alzheimer's pathology, primarily through a transient activation of brain inflammation. Also, a significant cognitive impairment persisted for at least 14 weeks after surgery compared to controls receiving anesthesia alone. Neither surgery nor anesthesia produced changes in normal non-transgenic animals.

"In the mice, there was a clear and persistent decrement in learning and memory caused by surgery as compared with inhalational anesthesia but only in the context of a brain made vulnerable by human Alzheimer-associated transgenes," notes Eckenhoff.

He also notes that at the time of surgery, the AD mice showed no outward symptoms of AD, despite having subtle evidence of ongoing neuropathology. "This timeline is analogous to both the age range and cognitive status of many of our patients presenting for a surgical procedure and suggests the window of vulnerability to surgery of the Alzheimer's brain extends into this pre-symptomatic period," says Eckenhoff. This period might be analogous to what is now called prodromal AD.

"On the other hand," cautions Maryellen Eckenhoff, PhD, a neuroscientist on the team, "the brain vulnerability seen in the AD mice may not translate well to people." The AD mice used, like all current mouse models of Alzheimer disease, more closely resemble the situation in familial Alzheimer disease, which constitutes only a small minority of patients. She points out that it is not yet clear whether results from AD mouse models will represent patients who eventually get late-onset, or "sporadic" Alzheimer disease. These mice are, however, the current standard of choice for screening new drugs and have yielded considerable insight into Alzheimer pathogenesis.

The mechanism linking surgery and the cognitive effects seems to be inflammation. An inflammatory process is well known to occur as a result of surgery, at least outside the central nervous system. How this inflammatory process gains access to the brain, and accelerates AD pathology in a persistent way is still unclear.

Visit link:
Surgery more profound effect than anesthesia on brain pathology, cognition in Alzheimer's mice

Baylor’s Cancer Genetics Laboratory at CAP ’12

CGL Logo

The Cancer Genetics Laboratory (CGL) is a combined effort of multiple departments at Baylor College of Medicine. The CGL provides cancer genetic testing along with expert interpretations of the test results. Our extensive menu ranges from karyotyping and FISH analysis to next-generation sequencing and cancer chromosomal microarrays.

Please
look for Baylor College of Medicine’s Cancer Genetics Laboratory (CGL) at the
upcoming College of American Pathologists Annual Meeting in San Diego
(September 9-12 Booth #616).  CGL invites
all to visit the booth and learn more about their new services.  Members of the CGL clinical team will be
available to discuss CGL’s options for clinical pathology testing including:

  • Oncology
    Microarrays
  • Cancer
    Sequencing Panels Using Next-Generation Technology
  • Cancer
    Exome Sequencing

Dr.
Federico Monzon, CGL’s Director of Molecular Pathology will be available to
discuss current & future offerings.

To
schedule a meeting with Dr. Monzon please email Scott Johnson at scottj@bcm.edu.  

Search for tests by name
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Quick Links

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Translational Imaging Impacting Personalized Health. From Cell, To Whole Animal, To Tissue

The World Molecular Imaging Congress (WMIC) 2012 Annual Meeting in being held in Dublin, Ireland this week (September 5 - 8, 2012).


PerkinElmerLearn more about pathway characterization, therapeutic effect and treatment at the cellular, whole body and tissue level through PerkinElmer's translational imaging solutions. Our broad offering of imaging and analysis solutions enables you to see and understand more in every area of research — from cellular imaging, to in vivo imaging, to pathology. With intuitive, high-performance software, broad portfolio of in vivo imaging reagents and leading imaging systems, effectively translate your research from the bench top and beyond. Visit PerkinElmer at booth #404 at WMIC to experience our translational imaging technologies first-hand.

Hear from Kevin Hrusovsky, SVP & President, PerkinElmer on Translational Imaging Impacting Personalized Health-An Academic and Industry Partnership, September 7, 2012, 6:15 PM - 7:45 PM at WMIC.

Join the WMIC Gala Event on September 8th at the Guinness Storehouse, with music by PerkinElmer's own Molecular Groove. Return to the 80's with us including special guest appearances.

Register for the Gala Event

LEARN MORE AT IN VIVO UNIVERSITY

Visit http://www.perkinelmer.com/tissueimaging for PerkinElmer’s Digital Pathology tools.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Journal of Pathology Informatics – New Articles Published


Cover Cover Cover
Utilization and utility of clinical laboratory reports with graphical elements

Brian H Shirts, Nichole Larsen, Brian R Jackson
J Pathol Inform 2012, 3:26 (25 August 2012)
[ABSTRACT]   [HTML FULL TEXT]   [PDF]   [Mobile HTML Full text ]   [EPub]

Diagnosis of dysplasia in upper gastro-intestinal tract biopsies through digital microscopy
Dorina Gui, Galen Cortina, Bita Naini, Steve Hart, Garrett Gerney, David Dawson, Sarah Dry
J Pathol Inform 2012, 3:27 (25 August 2012)
[ABSTRACT]   [HTML FULL TEXT]   [PDF]   [Mobile HTML Full text ]   [EPub]

Dynamic nonrobotic telemicroscopy via skype: A cost effective solution to teleconsultation
Sahussapont J Sirintrapun, Adela Cimic
J Pathol Inform 2012, 3:28 (25 August 2012)
[ABSTRACT]   [HTML FULL TEXT]   [PDF]   [Mobile HTML Full text ]   [EPub]

Experience with CellaVision DM96 for peripheral blood differentials in a large multi-center academic hospital system
Marian A Rollins-Raval, Jay S Raval, Lydia Contis
J Pathol Inform 2012, 3:29 (25 August 2012)
[ABSTRACT]   [HTML FULL TEXT]   [PDF]   [Mobile HTML Full text ]   [EPub]

Different tracks for pathology informatics fellowship training: Experiences of and input from trainees in a large multisite fellowship program
Bruce P Levy, David S McClintock, Roy E Lee, William J Lane, Veronica E Klepeis, Jason M Baron, Maristela L Onozato, JiYeon Kim, Victor Brodsky, Bruce Beckwith, Frank Kuo, John R Gilbertson
J Pathol Inform 2012, 3:30 (30 August 2012)
[ABSTRACT]   [HTML FULL TEXT]   [PDF]   [Mobile HTML Full text ]   [EPub]

A core curriculum for clinical fellowship training in pathology informatics
David S McClintock, Bruce P Levy, William J Lane, Roy E Lee, Jason M Baron, Veronica E Klepeis, Maristela L Onozato, JiYeon Kim, Anand S Dighe, Bruce A Beckwith, Frank Kuo, Stephen Black-Schaffer, John R Gilbertson
J Pathol Inform 2012, 3:31 (30 August 2012)
[ABSTRACT]   [HTML FULL TEXT]   [PDF]   [Mobile HTML Full text ]   [EPub]

Use of a wiki as an interactive teaching tool in pathology residency education: Experience with a genomics, research, and informatics inpathology course
Seung Park, Anil Parwani, Trevor MacPherson, Liron Pantanowitz
J Pathol Inform 2012, 3:32 (30 August 2012)
[ABSTRACT]   [HTML FULL TEXT]   [PDF]   [Mobile HTML Full text ]   [EPub]


Jpi_blogJpi_blogJpi_blog

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

PerkinElmer and Massachusetts General Hospital Pathology Collaborate to Develop a Complete Sequencing Informatics System for Cancer Research

Global leader in life sciences to help leading research hospital advance innovation in cancer research

WALTHAM, Mass., Aug 28, 2012 (BUSINESS WIRE) -- PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that it has entered into a collaboration with Dr. John Iafrate and Dr. Long Le of the Massachusetts General Hospital (MGH) Pathology Department and Cancer Center to develop a sequencing informatics system for profiling the genetic changes in tumors for use in advanced cancer research.

Based on PerkinElmer's Geospiza(R) informatics platforms, the new system is expected to help guide the development of cancer treatments by enabling genotype analysis to define key genetic targets from which clinically relevant information can be leveraged. Under the terms of the agreement, PerkinElmer will develop a highly automated sample preparation and data analysis system suitable for cancer genotyping in clinical research at the MGH Pathology Department and Cancer Center. PerkinElmer's Geospiza GeneSifter(R) Laboratory and Analysis edition software platform will be enhanced with sophisticated variant detection algorithms. The new system will also integrate existing laboratory processes and equipment with enhanced LIMS and data analysis capabilities.

The informatics system will support the cancer research of Dr. Long Le and Dr. John Iafrate of the MGH Pathology Department and Cancer Center. "A key challenge presented by next generation sequencing applications in clinical research is not only maintaining high efficiency and throughput via automation solutions, but also ensuring that the informatics driving the instrumentation provides transparency and traceability for the entire process," said Dr. Le.

Kevin Hrusovsky, president of Life Sciences & Technology at PerkinElmer, said, "Working with the MGH Pathology Department and Cancer Center to support their critically important cancer research is a deeply rewarding collaboration and is consistent with our goal to help researchers eradicate this deadly disease. We are delighted to provide MGH with a complete next generation sequencing informatics and sample preparation solution to help advance their medical research."

The MGH Pathology Department and Cancer Center are currently using the high quality service and data from PerkinElmer's DNA Sequencing Services group and deploys PerkinElmer's Sciclone(R) automated liquid handling platform and the NGS Express(TM) Workstation for benchtop sequencers.

For more information on PerkinElmer's Geospiza informatics offering, please visit http://www.geospiza.com

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.9 billion in 2011, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at http://www.perkinelmer.com .

SOURCE: PerkinElmer, Inc.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

More technology, better learning resources, better learning? Lessons from adopting virtual microscopy in undergraduate medical education.


Institution: Center for Learning Research, Department of Teacher Education, Faculty of Education, University of Turku, Turku, Finland. lhelle@utu.fi.

Abstract

The adoption of virtual microscopy at the University of Turku, Finland, created a unique real-world laboratory for exploring ways of reforming the learning environment. The purpose of this study was to evaluate the students' reactions and the impact of a set of measures designed to boost an experimental group's understanding of abnormal histology through an emphasis on knowledge of normal cells and tissues. The set of measures included (1) digital resources to review normal structures and an entrance examination for enforcement, (2) digital course slides highlighting normal and abnormal tissues, and (3) self-diagnostic quizzes. The performance of historical controls was used as a baseline, as previous students had never been exposed to the above-mentioned measures. The students' understanding of normal histology was assessed in the beginning of the module to determine the impact of the first set of measures, whereas that of abnormal histology was assessed at the end of the module to determine the impact of the whole set of measures. The students' reactions to the instructional measures were assessed by course evaluation data. Additionally, four students were interviewed. Results confirmed that the experimental group significantly outperformed the historical controls in understanding normal histology. The students held favorable opinions on the idea of emphasizing normal structures. However, with regards to abnormal histology, the historical controls outperformed the experimental group. In conclusion, allowing students access to high-quality digitized materials and boosting prerequisite skills are clearly not sufficient to boost final competence. Instead, the solution may lie in making students externally accountable for their learning throughout their training. Anat Sci Educ. © 2012 American Association of Anatomists.

Copyright © 2012 American Association of Anatomists.

Anat Sci Educ. 2012 Aug 28. doi: 10.1002/ase.1302. [Epub ahead of print]

Logo_en

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Lilly Diabetes Launches Mobile Application for Those Who Support People with Type 1 Diabetes

App serves as a teaching tool and can provide guidance for treatment with Lilly Glucagon for Injection (rDNA origin) during severe hypoglycemic events


Lilly_Glucagon_mobile_app_screenINDIANAPOLIS – September 4, 2012 – Lilly Diabetes today announced the release of a new mobile application designed for caregivers and healthcare providers who support people with type 1 diabetes. The Lilly Glucagon Mobile App is a tool to teach how to use Glucagon for Injection, through simulated practice. Glucagon, 1 mg (1 unit), is indicated to treat severe hypoglycemia (low blood sugar). Severe hypoglycemia due to insulin may result in loss of consciousness (insulin coma). The app is designed to help people be more prepared, and also  provide an opportunity to store locations and expiration dates of their Lilly Glucagon Emergency Kits. The Lilly Glucagon Mobile App is now available on the iTunes® store as a free download for iPhone® or iPad® mobile devices.

People with type 1 diabetes who experience severe hypoglycemia during insulin treatment may require glucagon, a hormone produced in the pancreas to raise blood sugar levels. Glucagon. U.S. Library of National Medicine. NIH. Updated September 2010. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000691/.  Although Glucagon is rarely needed and only used during a severe hypoglycemic event, individuals in the person’s support network, such as family members, teachers, coaches, trusted friends and colleagues, should be trained to give the medicine, which is injected with a syringe. The app can also be used by diabetes educators and school nurses as a teaching tool.


GlucagonappIn type 1 diabetes, the body does not produce insulin, a hormone produced by the pancreas in response to an increase in blood sugar, such as after a meal. As many as three million Americans may have type 1 diabetes. Each year more than 15,000 people under age 20 are diagnosed with the disease. Glucagon should not be used in patients who have pheochromocytoma or patients who are allergic to Glucagon.  Patients must inform relatives or close friends that if they become unconscious, medical assistance must always be sought. If a patient is unconscious, Glucagon can be given while awaiting medical assistance.

“Lilly Diabetes is committed to developing personalized solutions to help people with diabetes achieve their treatment goals and improve their outcomes,” said Matt Caffrey, U.S. Product Brand Director, Marketing Specialty, Lilly Diabetes. “The Lilly Glucagon Mobile App leverages the power and reach of mobile technology, providing another opportunity to support people living with type 1 diabetes. Lilly Diabetes is constantly striving to create new and better tools to support the diabetes community in a variety of ways.” 

The Lilly Glucagon Mobile App is an interactive tool to help caregivers better understand Glucagon’s role in diabetes management. Its purpose is to educate and prepare the caregiver on how to use Glucagon in the event of an emergency. The app was developed with input from healthcare providers and people with diabetes.  

The Lilly Glucagon Mobile App includes:
·        Information about severe hypoglycemia and Glucagon 
·        Simulated practice demonstrating how to prepare and inject Glucagon
·        Visual and audio emergency instructions
·        Tools to keep track of kit locations and alerts for expiration dates 
·        Important safety information

Important Safety Information for Glucagon 
What is the most important information about Glucagon?
·        Glucagon should not be used in patients with pheochromocytoma or who may be allergic to glucagon.
·        Patients need to tell their healthcare provider if they have been diagnosed with or have been suspected of having an insulinoma as glucagon should be used cautiously in this situation.
·        Anyone who may need to help patients during an emergency should become familiar with how to use glucagon before an emergency arises. Read the Information for the User provided in the kit.
·        Patients need to make sure that relatives or close friends know that if they become unconscious, medical assistance must always be sought. If a patient is unconscious, glucagon can be given while awaiting medical assistance.
·        The kit must not be used after the date stamped on the bottle label.
·        Questions concerning the use of this product should be directed to a doctor, nurse or pharmacist.

WARNING: PATIENTS MAY BE IN A COMA FROM SEVERE HYPERGLYCEMIA (HIGH BLOOD GLUCOSE) RATHER THAN HYPOGLYCEMIA. IN SUCH A CASE, THE PATIENTS WILL NOT RESPOND TO GLUCAGON AND WILL REQUIRE IMMEDIATE MEDICAL ATTENTION.

Who should not use glucagon?
Glucagon should not be used in patients who have pheochromocytoma or who are allergic to glucagon.

What should patients tell their doctor before taking glucagon?
Patients should tell their doctor about all medical conditions and prescription and over-the-counter drugs. Patients should tell their doctor if they have been diagnosed with or have been suspected of having pheochromocytoma or an insulinoma.

How should glucagon be used?
·        It is important to act quickly. Prolonged unconsciousness may be harmful.
·        Family and friends need to know to turn the patient on their side to prevent choking if they are unconscious.
·        The contents of the syringe are inactive and must be mixed with the glucagon in the accompanying bottle immediately before giving injection. Glucagon for Injection must not be prepared until it is ready to be used.
·        Glucagon should not be used unless the solution is clear and of a water-like consistency.
·        The usual adult dose is 1 mg (1 unit). For children weighing less than 44 lbs (20 kg), 1/2 adult dose (0.5 mg) is used. For children, 1/2 of the solution from the bottle (0.5 mg mark on syringe) should be withdrawn. The unused portion should be discarded.
·        Patients should eat as soon as they awaken and are able to swallow. A doctor or emergency services must be informed immediately.

What is some important Information about Low Blood Sugar (Hypoglycemia)?
·        Early symptoms of low blood sugar include: sweating, drowsiness, dizziness, sleep disturbances, palpitation, anxiety, tremor, blurred vision, hunger, slurred speech, restlessness, depressed mood, tingling in the hands, feet, lips, or tongue, irritability, lightheadedness, abnormal behavior, inability to concentrate, unsteady movement, headache, and personality changes. These symptoms may be different for each person and can happen suddenly.
·        If low blood sugar is not treated, it may progress to severe low blood sugar that can include: disorientation, seizures, unconsciousness, and death
·        Low blood sugar symptoms should be treated with a quick source of sugar which should always be carried with the patient. If symptoms do not improve or if the patient is unable to take a quick source of sugar, they should be treated with glucagon or with intravenous glucose at a medical facility.

What are the possible side effects of glucagon? 
·        Severe side effects are very rare, although nausea and vomiting may occur occasionally.
·        A few people may be allergic to glucagon or to one of the inactive ingredients in glucagon, or may experience rapid heart beat for a short while.
·        Patients who experience any other reactions which are likely to have been caused by glucagon should contact their doctor.

Patients and caregivers are encouraged to report negative side effects of Prescription drugs to the FDA. Visit http://www.fda.gov/medwatchor call 1-800-FDA-1088.

How should glucagon be stored?
·        Before dissolving glucagon with diluting solution, the kit should be stored at controlled room temperature between 20° to 25°C (68° to 77°F).
·        After glucagon is dissolved with diluting solution, it should be used immediately. Any unused portion should be discarded. Glucagon should be clear and of a water-like consistency at time of use.

For more safety information, please access Information for the User and Information for the Physician.

HI GLUC PR ISI [17JUL12]

The glucagon design is a trademark of Eli Lilly and Company. Glucagon is available by prescription only.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions—from medicines to support programs and more—to make lives better. For more information, visit http://www.lillydiabetes.com

About Eli Lilly and Company 
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers — through medicines and information — for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

NovoPath Showcases Smartphone App at CAP ‘12


PRINCETON, NJ, September 4, 2012 – NovoPath, Inc., a leader in Anatomic Pathology (AP) Best-of-Breed Software Solutions, announces the first smartphone apps for Android and Apple users, enabling secure on-the-go access to full-length AP reports.  The implementation of NovoNotifier Mobile means clinicians receiving AP reports from NovoPath partner laboratories now have a unique tool at their disposal, assisting in their quest to provide the very best care to their patients.  NovoNotifier Mobile will be featured on the NovoPath booth (#602) at the CAP ’12 Meeting, September 9-12, in San Diego.
 
According to a recent report from iPharma Connect 2012, over 80% of physicians are currently using smartphones, with adoption increasing at a tremendous rate.  Via NovoNotifier Mobile, Anatomic Pathology reports are now available in a continuous real-time portable format to many of these doctors.  NovoNotifier Mobile places results directly into the hands of the busy clinician, regardless of their location – be it in a point-of-care setting, at home, or anywhere in between.  This immediate access to lab generated anatomic pathology test results, enabled by mobile AP reporting, empowers the clinician to respond quicker – a significant improvement for the patient anxiously awaiting their diagnostic or prognostic outcome.
 
To access NovoNotifier Mobile, the clinician (working with a pathology lab using the NovoPath AP LIS Software Solution Version 8.0) is provided secure discreet user ID-based access to their patient’s anatomic pathology reports.  Following initial setup, AP reports are automatically sent via unattended delivery, with a “signal” sent to their smartphone notifying the physician that new reports are awaiting their review, at their convenience.  After viewing the report, the clinician has the option to preserve or delete the file – knowing it will be maintained on the lab’s website.  This affords clinicians the flexibility provided by immediate access, without tying up all the memory in their handheld.
 
Wally Soufi, NovoPath CEO, commented, “Mobile access means our partner lab’s clinicians no longer need to schedule time in their busy day to view web-based patient reports.  Via NovoNotifier Mobile, these same clinicians can now view AP reports in their entirety – in the same customized format developed by their pathology laboratory – anytime, anyplace.  The mobile view is 100% identical to the reports they have come to rely upon on their desktop. NovoPath is pleased to be the first to provide instant access to portable AP reports, and believes that this decrease in turn-around-time will translate to even better patient outcomes.”
About NovoPath, Inc.
 
NovoPath, Inc. develops and markets software solutions for the Anatomic Pathology Laboratory market segment that includes local, regional, national, in-house laboratories as well as community and university teaching hospitals and medical centers. Since the release of its flagship product in 1999, NovoPath, Inc. has focused exclusively on Anatomic Pathology. NovoPath's mission is to provide unique and unparalleled solutions and services to all aspects of the Anatomic Pathology sector in a way that improves workflow, reduces the probability of human error, ensures results accuracy for greater patient safety, protects patient confidentiality, and above all, produces more precise and informative diagnostic outcomes. More information is available at http://www.NovoPath.com.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Digital Pathology Market – Global Trends, Developments & Forecasts (2012 – 2017)


M&mBy: marketsandmarkets.com

Publishing Date: October 2012

Report Code: MD 1307

Discount on Prebooks 

 
             Single User License :: US $ 4650             Corporate User License ::US $ 7150           purchase report
download pdf  request for customisation

Digital pathology includes scanning systems enabled in part by virtual microscopy, which is the practice of converting glass slides into digital slides that can be viewed, managed, and analyzed using an integrated system. This includes hardware as well as software systems enabling image management and workflow. Systems for research purpose also include RUO, CE-IVD and FDA-cleared 510(k) image analysis. It is a key driver to getting the right slide to the right pathologist (Telepathology) and enables diagnostic collaboration between specialists and researchers and the promise of workflow enhancement and efficiency.

These systems are useful for preclinical hisopathological studies by CROs and pharmaceutical companies, clinical diagnosis (this may not include image interpretation), pathological slides in clinical research. Within this space, cancer & toxicological pathology is of specific importance.

This report investigates the current digital pathology market, technological advancements, activities, trends observed in the market, explore potential opportunities for companies involved in this space, integrate stakeholder perception and quantify these findings into future market projections and geographic analysis.

request for customization

M&m

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

No apology over surgery botch-up

At least one woman who was wrongly operated on after a botch-up in reporting pathology results has not received an apology, and others were told of the mistake over the phone "quite some time" later, a panel of experts looking into the mix-ups has found.

In June the Ministry of Health convened a panel of experts to look into five cases where woman had unnecessary surgery because of mistakes in reporting pathology results.

One of the cases involved a woman having part of her jaw cut away after being wrongly diagnosed with cancer of the mouth.

Another woman had a mastectomy by mistake after her breast biopsy was swapped with another.

A Herald on Sunday investigation found six woman had been affected by errors made in pathology laboratories.

The panel of experts yesterday reported back that there was five incidents over a two-year period.

Four incidents involved breast biopsy tissue and the fifth involved oral tissue.

Four of the errors resulted from transposition of specimens with those of other patients during the laboratory process. The fifth error resulted from a misinterpretation of the specimen, it reported.

In compiling the report panel representatives met with four of the woman who reported on their experiences during and after the case.

The response from health providers once the mix-up was realised "generally was short in duration and largely unsatisfactory", it said.

Original post:
No apology over surgery botch-up

Aperio ePathology NETWORK to Improve Communication among Pathologists, Pathology Sub-Specialists and Other Physicians

VISTA, Calif. & OXFORD, England--(BUSINESS WIRE)--

Aperio, the global leader in ePathology solutions, bringing digital pathology into standard practice, is showcasing their intuitive, easy-to-use solution that connects pathologists across geographical boundaries and enables enhanced communication across the patient care team. Whether at the office or on the go, the Aperio ePathology NETWORK provides the access pathologists need to stay connected and supports applications for intraoperative consultation, as well as internal and external consultation. The unveiling of the Aperio ePathology NETWORK, is taking place at the European Congress of Pathology on September 8-11 in Prague, and at CAP 12The Pathologists Meetingin San Diego, September 9-12, 2012. Aperio expects to begin shipment of the new software to customers before the end of October.

Healthcare organizations are embracing ePathology, taking digital images into clinical use, said Jared N. Schwartz, M.D., Ph.D., F.C.A.P., Aperios chief medical officer. The Aperio ePathology NETWORK delivers a software solution that makes it easy to adopt ePathology into routine patient care by effectively connecting the care team across disparate hospital locations.

The Aperio ePathology NETWORK raises the bar in patient care by enabling very quick access to sub-specialty expertise for difficult cases. The patient has access to the right sub-specialist and the pathologist has peace of mind, said Dr. Olga Ioffe, professor of pathology at the University of Maryland, School of Medicine. An additional benefit of the NETWORK is that those pathologists covering surgery centers can interpret intraoperative consultations remotely, reducing or eliminating travel.

Aperio will also launch its newest ePathViewer, an easy-to-use application for viewing eSlide images anywhere, at any time, via an iPAD or iPhone. The Aperio ePathViewer will connect to the NETWORK and also supports several pre-configured websites including the Rosai Collection, Aperio eSlide Hosting and Aperio eSlideShare. The Aperio ePathViewer will be available in mid-September for download at the App Store.

We invite you to view the new Aperio ePathology NETWORK at ECP 12 booth #39 and CAP 12 booth #211.

About Aperio

For over a decade, Aperio has advanced the technology that enables glass slides to be digitized and securely shared with others. Aperio products are transforming the practice of pathology in hospitals, reference labs, and pharmaceutical and research institutions around the world. Aperio products are FDA cleared for specific clinical applications, and are intended for research and educational use for other applications. They are not approved by the FDA for primary diagnosis. The Aperio IOC solution should not be used when permanent sections on glass slides are not going to be available for a primary diagnosis. For clearance updates, specific product indications, and more information, please visit http://www.aperio.com.

Link:
Aperio ePathology NETWORK to Improve Communication among Pathologists, Pathology Sub-Specialists and Other Physicians